Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SET pseudogene 11 (SETP11) is a genomic DNA sequence similar to the SET nuclear proto-oncogene but is predicted to be a nonfunctional pseudogene[3][4]. Pseudogenes are typically derived from duplication or retrotransposition events and harbor mutations that disrupt their protein-coding capacity, making them incapable of expressing functional proteins[2][4]. While some pseudogenes have been shown to regulate gene expression via noncoding RNA mechanisms such as microRNA sponging, antisense RNA, or long non-coding RNAs, there is no current evidence or literature suggesting SETP11 has any functional, diagnostic, or therapeutic relevance[3][5][6]. Overall, SETP11 is not considered a classical therapeutic target, and its designation as such is likely a misinterpretation or error. For structured data extraction or ontological mapping, SETP11 should be listed as a pseudogene, not a target. It lacks relevance as a protein, receptor, enzyme, or transporter, and has no documented involvement in disease or therapeutic contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SET pseudogene 11 (SETP11).